When Science magazine named cancer immunotherapy the 2013 “Breakthrough of the Year” last December, we knew that it was not only an affirmation of what we have been dedicated to for more than six decades, but that it would be the beginning of an exciting new era in cancer treatment. This past year served as a testament of the accelerated progress being made in the field of cancer immunotherapy research, which would not be possible without the accomplishments here at the Cancer Research Institute.
Some highlights from this year include:
Learn more about our programs and the advancements we’ve made this year.
View our 2014 Annual Report
FDA Approves New Immunotherapy for Leukemia
Read Previous Article
Faces of CRI
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI hosted a Twitter Chat, moderated by STAT’s Sharon Begley, discussing takeaways from the ASCO19 conference last week.
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers, and cellular immunotherapy.